Search

Displaying results 4361 - 4370 of 10000 in total
  1. Drug

    Levopropoxyphene

    go.drugbank.com/drugs/DB06793
    ApprovedWithdrawn

    Levopropoxyphene is a stereoisomer of propoxyphene in the form of 2S, 3R enantiomer. It was sold as an antitussive, but it was removed from the market in the 70s. … [T133] Levopropoxyphene was developed by Lilly and FDA approved on March 21st, 1962. This drug presented different dosages and it was administered as a capsule or suspension.

  2. Drug

    Estramustine

    go.drugbank.com/drugs/DB01196
    ApprovedWithdrawn

    A nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties.

    Synonyms: Estradiol 3-(N,N-bis(2-chloroethyl)carbamate)
  3. Drug

    ADH-1

    go.drugbank.com/drugs/DB05485
    Investigational

    As many tumors become more aggressive, invasive, and malignant, researchers have found that N-cadherin is expressed in greater amounts, making it an important target for developing anti-cancer treatments … ADH-1 may have utility in a wide variety of cancers as N-cadherin is overexpressed in a variety of tumors.

    Synonyms: l-cysteinamide, n-acetyl-l-cysteinyl-l-histidyl-l-alanyl-l-valyl-, cyclic (1-5)-disulfide
  4. Drug

    LCP-AtorFen

    go.drugbank.com/drugs/DB05769
    Investigational

    LCP-AtorFen is designed to be a once daily tablet offering a powerful and safe treatment of high cholesterol levels, addressing three primary cardiovascular risk factors: low density lipoprotein cholesterol … LCP-AtorFen is a fixed-dose combination therapy for the treatment of high cholesterol levels combining atorvastatin (the active ingredient of Lipitor®) and the lowest dose of fenofibrate without food effect

  5. Drug

    Phenoxypropazine

    go.drugbank.com/drugs/DB09251
    ApprovedWithdrawn

    It was marketed as an antidepressant in 1961 but was later withdrawn in 1966 because of its hepatotoxic potential. … Phenoxypropazine is a non-selective and irreversible monoamine oxidase enzyme inhibitor (MAOI), belonging to the _hydrazine_ chemical class.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  6. Drug

    Selenomethionine Se-75

    go.drugbank.com/drugs/DB09400
    Approved

    Mixtures: Megavite Rx
  7. Drug

    Endostatin

    go.drugbank.com/drugs/DB06423
    Investigational

    Categories: Compounds used in a research, industrial, or household setting, Non-Fibrillar Collagens
  8. Drug

    Pivhydrazine

    go.drugbank.com/drugs/DB09252
    ApprovedWithdrawn

    In 1960, it was widely used as an antidepressant agent but it is now discontinued. … Pivhydrazine, also known as pivazide, is a member of the hydrazine family with irreversible and non-selective inhibitory activity against monoamine oxidases.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  9. Drug

    Nilvadipine

    go.drugbank.com/drugs/DB06712
    Approved

    Nilvadipine is a calcium channel blocker (CCB) for the treatment of hypertension.

  10. Drug

    Methscopolamine bromide

    go.drugbank.com/drugs/DB00462
    Approved

    A muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors.

    Synonyms: N-methylhyoscine bromide, N-methylscopolammonium bromide